PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis

BACKGROUND: As an emerging treatment strategy for triple-negative breast cancer (TNBC), immunotherapy acts in part by inducing ferroptosis. Recent studies have shown that protein arginine methyltransferase 5 (PRMT5) has distinct roles in immunotherapy among multiple cancers by modulating the tumor m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhe, Li, Ruolei, Hou, Niuniu, Zhang, Juliang, Wang, Ting, Fan, Pengyu, Ji, Cheng, Zhang, Bo, Liu, Liuyin, Wang, Yaping, Kong, Jing, Yao, Qing, Duan, Jie, Zhao, Ge, Ling, Rui, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410861/
https://www.ncbi.nlm.nih.gov/pubmed/37380368
http://dx.doi.org/10.1136/jitc-2023-006890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410861/
https://www.ncbi.nlm.nih.gov/pubmed/37380368
http://dx.doi.org/10.1136/jitc-2023-006890

Ejemplares similares